Hostname: page-component-586b7cd67f-rcrh6 Total loading time: 0 Render date: 2024-11-27T14:39:21.216Z Has data issue: false hasContentIssue false
  • English
  • Français

Platelet Monoamine Oxidase B Activity in “de novo” and L-Dopa Treated Parkinsonian Patients and Controls

Published online by Cambridge University Press:  18 September 2015

Wilfried Kuhn ,
Thomas Müller ,
Anja Gerstner ,
Regina Winkel  and
Mario E. Goetz
Wilfried Kuhn
Affiliation:
Department of Neurology, Ruhr-University of Bochum, St.-Josef Hospital, Bochum, Germany.
Thomas Müller*
Affiliation:
Department of Neurology, Ruhr-University of Bochum, St.-Josef Hospital, Bochum, Germany.
Anja Gerstner
Affiliation:
Department of Neurology, Ruhr-University of Bochum, St.-Josef Hospital, Bochum, Germany.
Regina Winkel
Affiliation:
Department of Neurology, Ruhr-University of Bochum, St.-Josef Hospital, Bochum, Germany.
Mario E. Goetz
Affiliation:
Department of Neurochemistry, Department of Psychiatry, University of Wüirzburg, Wüirzburg, Germany.
*
Department of Neurology, Ruhr-University of Bochum, St.-Josef Hospital, Gudrunstr, 56 D-44791 Bochum, Germany.
Rights & Permissions [Opens in a new window]

Abstract:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Objective:

Previous studies demonstrated controversial results regarding monoamine oxidase B (MAO-B) activity in platelets in the periphery in parkinsonian patients (PD).

Subjects and Methods:

Therefore we determined platelet MAO-B activity in three age- and sex-matched groups of 17 untreated, so called “de novo” patients with Parkinson's disease (PD), 17 parkinsonian patients, receiving levodopa, and 17 controls by a radio enzymatic assay.

Results:

No significant differences of MAO-B activity appeared.

Conclusion:

This result suggests that phenotypic determination of MAO-B activity in platelets may not be used as peripheral marker in PD and that levodopa treatment does not alter MAO-B activity in the periphery.

Type
Original Articles
Information
Canadian Journal of Neurological Sciences , Volume 25 , Issue 3 , August 1998 , pp. 249 - 251
Copyright
Copyright © Canadian Neurological Sciences Federation 1998

References

REFERENCES

1.Riederer, P, Konradi, C, Schay, V, et al. Localization of MAO-A and MAO-B in human brain: a step in understanding the therapeutic action of L-deprenyl. Adv Neurol 1987; 45: 111–118.Google Scholar
2.Konradi, C, Riederer, P, Jellinger, K, Denney, R. Cellular action of MAO inhibitors. J Neural Transm Suppl 1987; 25: 15–25.Google ScholarPubMed
3.Koide, Y, Koide, N, Ross, S, Sääf, J, Wetterberg, L. Monoamine oxidase in human platelets. Kinetics and methodological aspects. Biochem Pharmacol 1981; 30: 2893–2900.CrossRefGoogle ScholarPubMed
4.Checkoway, H, Costa, LG, Woods, JS, et al. Peripheral blood cell activities of monoamine oxidase B and superoxide dismutase in Parkinson’s disease. J Neural Transm Park Dis Dement Sect 1992; 4: 283–290.CrossRefGoogle ScholarPubMed
5.Cohen, G. Monoamine oxidase, hydrogen peroxide, and Parkinson’s Disease. In: Yahr, MD, Bergmann, KJ, eds. Advances in Neurology. New York: Raven Press, Vol 45; 1986: 119–125.Google Scholar
6.Halliwell, B. Free radicals, antioxidants, and human disease: curiosity, cause, or consequence? Lancet 1994; 344: 721.CrossRefGoogle ScholarPubMed
7.Riederer, P, Konradi, C, Hebenstreit, G, Youdim, MBH. Neurochemical perspectives to the function of monoamine oxidase. Acta Neurol Scand 1989; 80 (Suppl 126): 41–45.CrossRefGoogle Scholar
8.Bradford, MM. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248–254.CrossRefGoogle Scholar
9.Wurtman, RJ, Axelrod, J. A sensitive and specific assay for the estimation of monoamine oxidase. Biochem Pharmacol 1963; 12: 1439–1441.CrossRefGoogle ScholarPubMed
10.Tipton, KF, Youdim, MBH. The assay of monoamine oxidase. In: Parvez, S, Nagatsu, T, Nagatsu, I, Parvez, H, eds. Methods Biogenic Amine Res, Amsterdam: Elsevier, 1983: 441–465.Google ScholarPubMed
11.Mann, JJ, Stanley, M, Kaplan, RD, Sweeney, J, Neophytides, A. Central catecholamine metabolism in vivo and the cognitive and motor deficits in Parkinson’s disease. J Neurol Neurosurg Psychiatry 1983; 46: 905–910.CrossRefGoogle ScholarPubMed
12.Zeller, EA, Boshes, B, Arbit, J, et al. Molecular biology of neurological and psychiatric disorders. I. Effects of Parkinsonism, age, sex, and L-Dopa on platelet monoamine oxidase. J Neural Transm 1976; 176; 39: 63–77.CrossRefGoogle ScholarPubMed
13.Steventon, GB, Sturman, SG, Heafield, MTE, et al. Platelet monoamine oxidase B in Parkinson’s Disease. J Neural Transm PD Sect 1989; 1: 255–261.CrossRefGoogle ScholarPubMed
14.Jarman, J, Glover, V, Sandler, M, Turjanski, N, Stern, G. Platelet monoamine oxidase B activity in Parkinson’s Disease: a reevaluation. J Neural Transm PD Sect 1993; 5: 1–4.CrossRefGoogle ScholarPubMed
15.Sandler, M, Glover, V, Clow, A, Jarman, J. Monoamine oxidase-B inhibitors and Parkinson’s disease. A role for superoxide dismutase? In: Narabayashi, H, Nagatsu, T, Yanagisawa, N, Mizuno, Y, eds. Advances in Neurology, New York: Raven Press, 1993: 238–241.Google ScholarPubMed
16.Lee, DH, Mendoza, M, Dvorozniak, MT, et al. Platelet monoamine oxidase in Parkinson patients: effect of l-deprenyl therapy. J Neural Transm PD Sect 1989; 1: 189–194.CrossRefGoogle ScholarPubMed
17.Danielczyk, W, Streifler, M, Konradi, C, Riederer, P, Moll, G. Platelet MAO-B activity and the psychopathology of Parkinson’s disease, senile dementia and multiinfarct dementia. Acta Psychiatr Scand 1988; 78: 730–736.CrossRefGoogle Scholar
18.Humfrey, CDN, Steventon, G.B, Sturman, SG, et al. Monoamine oxidase substrates in Parkinson’s disease. Biochem Pharmacol 1990; 40: 2562–2564.CrossRefGoogle ScholarPubMed
19.Steventon, G, Humfrey, C, Sturman, S, Waring, RH, Williams, AC. Monoamine oxidase B and Parkinson’s disease. Lancet 1990; 20: 180.CrossRefGoogle Scholar
20.Kuiper, MA, Konings, CH, Bergmans, PLM, Wolters, E Ch. Monoamine oxidase-B activity in untreated and treated Parkinson patients. In: Abstracts of the 10th International Symposium on Parkinson’s disease, 1991; Tokyo: 182.Google Scholar
21.Kurth, JH, Kurth, MC, Poduslo, SE, Schankhaus, JD. Association of a monoamine oxidase B allele with Parkinson’s disease. Ann Neurol 1993; 33: 368–372.CrossRefGoogle ScholarPubMed
22.Hotamisligil, GS, Girmen, AS, Fink, JS, et al. Hereditary variations in monoamine oxidase as a risk factor for Parkinson’s Disease. Mov Disord 1994; 9: 305–310.CrossRefGoogle ScholarPubMed
23.Ho, SL, Kapadi, L, Ramsden, DB, Williams, AC. An allelic association study of monoamine oxidase B in Parkinson’s disease. Ann Neurol 1995; 37: 403–405.CrossRefGoogle ScholarPubMed